In-Depth Hepatocellular Carcinoma Drugs Market Report: Business Trends, Growth Factors, and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Hepatocellular Carcinoma Drugs Market Expected to Be in 2029?
The market size for drugs treating hepatocellular carcinoma has seen robust growth over the recent past. It’s projected to expand from $1.16 billion in 2024 to $1.25 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. Factors contributing to growth in the historic period include a rise in disease incidence, progress in cancer research, enhancements in global healthcare infrastructure, regulatory approvals, as well as initiatives geared towards raising awareness and promoting early diagnosis.
The market size of drugs for hepatocellular carcinoma is predicted to experience significant growth in the upcoming years, reaching $1.72 billion by 2029 and expanding at a compound annual growth rate (CAGR) of 8.4%. This growth during the forecast period is likely to stem from enhancements in targeted therapies, a rising elderly population, trends towards personalised healthcare, and the worldwide increase in access to treatment. Key trends for the forecast period encompass innovative therapy accessibility, patient-focused care, advancements in regulations, strategies to combat drug resistance, and collaborative research endeavours.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp
What Are The Contributors To Demand In The Hepatocellular Carcinoma Drugs Market?
Predicted advancements in the hepatocellular carcinoma drug market are due to the mounting incidences of hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a severe malignant affliction of the liver, taking first place in liver cancer forms. This disease emerges predominantly from hepatocyte cells, the liver’s primary cellular component. In most instances, causes of HCC can be traced back to hepatitis B or C and cirrhosis. With hepatocellular carcinoma rates increasing consistently, the need for competent hepatocellular carcinoma drugs has escalated to manage and treat the disease effectively. For example, in 2023, the American Cancer Society, Inc., a nation-wide volunteer health organization committed to cancer treatment and eradication, projected that the number of women diagnosed with liver cancer in the United States would increase from 12,660 in 2022 to 13,230 in 2023. Hence, the enlargement of the hepatocellular carcinoma drug market is directly connected to the increasing instances of hepatocellular carcinoma.
What Segmentation Categories Are Included In The Hepatocellular Carcinoma Drugs Market Analysis?
The hepatocellular carcinoma drugs market covered in this report is segmented –
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy
What Upcoming Trends Are Expected To Impact The Hepatocellular Carcinoma Drugs Market Globally?
Leading enterprises in the hepatocellular carcinoma drugs market are innovating with lab-synthesized molecules like monoclonal antibodies (mAb) to meet an expanding customer reach, boost sales, and enhance revenue. Monoclonal antibodies are scientifically engineered molecules that are designed to imitate the body’s natural defense mechanism against harmful organisms such as viruses or bacteria. For example, in October 2022, AstraZeneca PLC, a pharmaceutical and biotechnology entity based in the UK, achieved the FDA approval for its hepatocellular carcinoma (HCC) treatment, combining Imjudo (tremelimumab) and Imfinzi (durvalumab), intended for adult patients. Imfinzi, a unique human monoclonal antibody, binds effectively to the PD-L1 protein, restraining its interaction with PD-1 and CD80 proteins and, in turn, prevents the tumor from escaping the body’s immune action, thereby heightening immune responses. On the other hand, Imjudo, a human monoclonal antibody specifically designed to target the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity. It inhibits CTLA-4 function, promoting T-cell activation, and primes the immune response against cancer cells, and induces the elimination of cancerous cells.
Who Are The Top-Ranked Companies In The Hepatocellular Carcinoma Drugs Market Today?
Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.
Get The Full Report Here:
How Is Hepatocellular Carcinoma Drugs Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10809&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
